Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 745 shares, a growth of 102.4% from the December 31st total of 368 shares. Based on an average daily trading volume, of 3,722 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 3,722 shares, the days-to-cover ratio is presently 0.2 days.

Ascentage Pharma Group International Trading Down 1.2%

Shares of NASDAQ:AAPG opened at $25.00 on Friday. The business’s 50 day moving average price is $28.49 and its 200-day moving average price is $34.87. Ascentage Pharma Group International has a 1 year low of $17.09 and a 1 year high of $48.45. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors have recently modified their holdings of AAPG. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth about $96,000. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000. Chevy Chase Trust Holdings LLC acquired a new position in shares of Ascentage Pharma Group International during the second quarter valued at approximately $227,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter worth approximately $391,000.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on AAPG shares. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a report on Monday, November 24th. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Piper Sandler started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target on the stock. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.